Skip to content

ENDOMET

ENDOmetrial cancer detection using DNA METhylation. A self-test to detect endometrial cancer using DNA methylation markers. - ENDOMET

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON57942
Enrollment
385
Registered
2025-06-17
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial cancer

Interventions

MeD-scan test

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Women with a first episode post-menopausal vaginal bleeding and/or other symptoms that are a reason to undergo gynaecological examination to detect or exclude endometrial cancer. - Written informed consent.

Exclusion criteria

Exclusion criteria: - Women who visit the gynaecologist for recurrent post-menopausal vaginal bleeding <1 year after their first episode. - Other gynaecological malignancies in their history in the past 5 years. 

Design outcomes

Primary

MeasureTime frame
Diagnostic accuracy of the MeD-Scan test (both in vaginal self-swab and cervical cytology).

Secondary

MeasureTime frame
Cost-effectiveness analysis of the MeD-Scan test compared to standard care.

Countries

Netherlands

Contacts

Public ContactC.B. Berg

Erasmus MC, Universitair Medisch Centrum Rotterdam

c.vandenberg@erasmusmc.nl010-704 07 04

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)